Assembly Biosciences reports positive interim Phase 1a results for ABI-1179 in recurrent genital herpes

ASSEMBLY BIOSCIENCES, INC.

ABI-1179 had a half-life of ~4 days and high exposure across 50mg-300mg doses, supporting once-weekly oral dosing.
ABI-1179 was well-tolerated with no serious adverse events and all treatment-emergent AEs mild and unrelated.
Company plans to move directly into Phase 1b, running concurrently with Phase 1b of ABI-5366.
Interim Phase 1b data for both ABI-1179 and ABI-5366 anticipated in fall 2025.
ABI-1179 contributed by Gilead Sciences under the Assembly Bio-Gilead collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.